Entero Healthcare Stock Jumps 33% in a Week, Hits New High

Entero’s Rally Puts Earnings Momentum and Growth Targets to the Test

A sharp run-up follows strong quarterly growth, but investors will be watching whether margins and cash generation keep pace.

Quarterly growth gives the rally an earnings backdrop

Entero shares rose 4% to ₹2,095.30 in intraday trade on the BSE, setting a new high, before trading at ₹2,090, up 3%, at 2:51 p.m. The move came as the broader market was largely range-bound: the Sensex was up 0.11% at that time. The stock had gained 33% over the past week and was up 122% from its 52-week low of ₹944, touched on December 29, 2025.

The company’s July–September 2026 quarter provided a fundamental support for investor interest. Revenue increased 33% year on year to ₹2,087 crore, while profit after tax rose 66% to ₹60.70 crore. EBITDA margin improved by 140 basis points to 5.3%, which the company attributed to cost discipline and a higher contribution from MedTech.

Organic growth of 18% was also ahead of the pharma market, according to the company. That matters because growth from existing operations can offer a more durable base than expansion that relies only on acquisitions. Entero has recorded organic growth of 17–20% over the past four quarters, supported by product additions, greater customer wallet share and underlying demand.

MedTech and cash generation shape the next phase

MedTech is emerging as an additional growth avenue, contributing more than 15% of consolidated revenue. The opportunity, as described by analysts, lies in adding product categories, reaching more customers in existing markets and building manufacturer partnerships. A larger contribution could support growth and margins, but the benefit will depend on the company’s ability to expand the business profitably.

Management expects FY27 revenue growth of 23% to be achievable and indicated that a strong first half could allow the company to exceed that guidance. The outlook includes organic expansion and the calendarisation impact of recent acquisitions, but excludes future deals. Jefferies said the company expects operating cash flow-to-EBITDA conversion of 50%; operating cash flow of more than ₹200 crore in FY27 could support growth investment, including acquisitions or higher stakes in partly owned subsidiaries.

Over three years, management expects revenue growth above 20% and EBITDA margins above 6%. These are targets, not assured outcomes. Execution, cash conversion and the returns from any acquisition will be important in assessing whether the growth plan strengthens the business.

The share price is approaching cited analyst targets

ICICI Securities and Jefferies retained Buy ratings, with both citing a target price of ₹2,100, though their valuation approaches differ. With the shares trading around ₹2,090 during the session, those targets provide limited headroom from the quoted level; they are brokerage estimates, not a guarantee of future returns. The recent 33% weekly rise also means investors should separate the company’s improving operating performance from the pace at which the market has priced it in.

The investment case therefore rests on continued organic growth, further margin improvement and the conversion of earnings into cash. Any acquisitions could add to growth, but the company’s ability to integrate them and preserve returns will matter. The cited outlook is encouraging, yet the sharp share-price move leaves less room for any shortfall to be overlooked.

Key Highlights

• Entero shares gained 33% in a week and reached a new BSE high of ₹2,095.30.
• Quarterly revenue rose 33% to ₹2,087 crore and profit after tax increased 66% to ₹60.70 crore.
• EBITDA margin expanded 140 basis points year on year to 5.3%.
• MedTech contributed more than 15% of consolidated revenue and is identified as a further growth avenue.
• Management expects FY27 revenue growth of 23% to be achievable; the guidance excludes future acquisitions.

Investor Note: Entero’s operating momentum and margin gains are positive, but after a steep rally, investors may want to track delivery against growth and cash-flow targets, alongside the returns from any acquisitions, rather than relying on price momentum alone.